Prolotherapy produces real, measurable pain relief for certain musculoskeletal conditions, but the strength of evidence varies widely depending on which body part and which problem you are talking about. The best-studied use is for knee osteoarthritis, where randomized controlled trials show meaningful improvements in pain and function compared to saline injections. For tendon injuries, jaw disorders, and back pain, the picture is less clear: positive results exist, but the studies tend to be smaller and more prone to bias. What makes prolotherapy tricky to evaluate is that the treatment itself is simple and cheap, yet the research landscape is a patchwork of small trials covering different joints, different injection solutions, and different comparison groups.
What Happens When Dextrose Gets Injected Into a Joint
The most common form of prolotherapy involves injecting a concentrated sugar solution, usually dextrose at 10 to 25 percent, into or around a damaged joint, tendon, or ligament. The traditional explanation is that this triggers a localized inflammatory response, which in turn stimulates the body’s healing machinery to lay down new tissue. That story is plausible but still not fully proven. An in vitro study published in 2025 found that fibroblasts (the cells responsible for building connective tissue) exposed to dextrose concentrations used in clinical practice showed increased proliferation 48 hours after exposure, supporting the idea that the sugar solution kicks off a growth response.1PubMed Central. In Vitro Model Exploring the Mechanisms of Dextrose Prolotherapy: Fibroblasts Exposed to Clinical Concentrations of Dextrose Exhibit Significant Rebound Effects 48 Hours After Exposure
On the inflammation side, a study of human tenocytes (tendon cells) confirmed that prolotherapy solutions triggered upregulation of key inflammatory markers like interleukin-8 and cyclooxygenase-2, along with elevated prostaglandin E2, a well-known driver of inflammation.2PubMed Central. Prolotherapy Induces an Inflammatory Response in Human Tenocytes In Vitro Animal models add another layer: rats with tendon injuries treated with dextrose at both 15 and 25 percent concentrations showed significantly improved collagen fiber organization, with the fibers becoming more compact and parallel rather than the disorganized mess typically seen in injured tendons.3PubMed Central. Dextrose prolotherapy at varying concentrations ameliorates tendon injury via IGF-2R: an integrated study of Mendelian randomization and an animal model
One complication with the inflammation theory is that the inflammatory signal from prolotherapy solutions does not always exceed what you get from simply sticking a needle in and injecting saline. A rat study examining three different prolotherapy solutions found that inflammation increased after injection compared to doing nothing, but not consistently compared to saline or a needlestick alone.4PubMed Central. Early inflammatory response of knee ligaments to prolotherapy in a rat model That finding raises a question researchers have not fully resolved: how much of prolotherapy’s benefit comes from the dextrose itself versus the mechanical act of injection, or even the repeated clinical attention and structured follow-up that comes with any injection-based treatment protocol.
The Knee Osteoarthritis Evidence
Knee osteoarthritis is where prolotherapy has the most clinical evidence, and the results are encouraging. A 2020 randomized controlled trial published in the Annals of Family Medicine compared intra-articular dextrose injections to blinded saline injections in patients with knee OA. At one year, the dextrose group showed significantly better pain scores, function scores, and quality-of-life measures compared to saline. No adverse events were reported.5PubMed Central. Efficacy of Intra-Articular Hypertonic Dextrose (Prolotherapy) for Knee Osteoarthritis: A Randomized Controlled Trial That trial is noteworthy because it used a true blinded control, meaning patients did not know whether they received dextrose or saline, which helps separate the drug effect from placebo.
Meta-analyses paint a broadly positive but cautious picture. A systematic review in Scientific Reports pooled data and found prolotherapy significantly outperformed exercise alone on pain, function, and composite outcome scores.6Scientific Reports. Hypertonic dextrose injections (prolotherapy) in the treatment of symptomatic knee osteoarthritis: A systematic review and meta-analysis A separate meta-analysis concluded that prolotherapy offers potential benefits for pain in knee OA, but flagged that the studies carry a high risk of bias. Based on the two strongest trials available, the authors gave dextrose prolotherapy a “B” strength of recommendation for knee OA, and a “C” recommendation for patients with limited alternative options, reflecting the treatment’s safety profile.7PubMed Central. Dextrose prolotherapy in knee osteoarthritis: A systematic review and meta-analysis A comprehensive review further noted that prolotherapy appears to play some role in cartilage growth and has been shown to improve stiffness, pain, function, and quality of life in knee OA.8PubMed Central. A Comprehensive Update of Prolotherapy in the Management of Osteoarthritis of the Knee
That “B” rating is worth understanding in context. It means the evidence is reasonably consistent and comes from decent-quality studies, but is not yet strong enough to call definitive. For a treatment that costs very little per session and has a mild side-effect profile, many practitioners view that as a favorable risk-to-benefit ratio, especially in patients who want to avoid or delay surgery.
Tendon Problems and Tennis Elbow
Tendons are where prolotherapy research gets messier. A systematic review of randomized controlled trials on sports-related tendinopathies found that for lateral epicondylitis (tennis elbow), prolotherapy was superior to the control group in half the studies examined. In the trials that showed benefit, patients receiving prolotherapy saw improvements of roughly 40 to 50 percent on validated elbow function scores, while control groups showed no significant improvement and did not reach the threshold considered clinically meaningful.9PubMed Central. Prolotherapy in the Treatment of Sports-Related Tendinopathies: A Systematic Review of Randomized Controlled Trials One study within that review found that prolotherapy with dextrose outperformed hyaluronic acid injections for pain with activity, pain at night, pain at rest, and arm disability scores.
However, a trial that combined prolotherapy with physiotherapy for tennis elbow found that at one year, all treatment groups improved substantially from baseline, but there were no significant differences between prolotherapy alone, physiotherapy alone, and the combination.10PubMed Central. Prolotherapy injections and physiotherapy used singly and in combination for lateral epicondylalgia: a single-blinded randomised clinical trial This raises a familiar question in prolotherapy research: when natural healing over time brings everyone to a good place, is the injection itself doing the heavy lifting, or is it accelerating a recovery that would have happened anyway?
For patellar tendinopathy (jumper’s knee) and chronic plantar fasciitis, smaller studies show positive results but with limited power to draw firm conclusions. A review of patellar tendon studies found increases in validated function scores and no serious adverse events across all included studies.11SpringerOpen / Journal of Experimental Orthopaedics. Sclerotherapy and prolotherapy for chronic patellar tendinopathies – a promising therapy with limited available evidence, a systematic review For lower-limb tendons and fascia overall, a systematic review found no adverse events following prolotherapy injections in any study reviewed.12PubMed Central. Effectiveness and safety of prolotherapy injections for management of lower limb tendinopathy and fasciopathy: a systematic review The pattern across tendon research is consistent: prolotherapy generally helps, rarely harms, but the studies are too small and heterogeneous to produce the kind of rock-solid evidence that would change clinical guidelines.
Jaw Disorders
Temporomandibular joint (TMJ) dysfunction is one of the more intriguing areas for prolotherapy, particularly for people with hypermobile jaws that dislocate or sublux. A preliminary randomized, double-blind, placebo-controlled trial found that prolotherapy with 10 percent dextrose produced significant reduction in maximum mouth opening (which is the goal when hypermobility is the problem) and reduced locking episodes. The benefits persisted through the follow-up period.13PubMed. The efficacy of dextrose prolotherapy for temporomandibular joint hypermobility: a preliminary prospective, randomized, double-blind, placebo-controlled clinical trial
A longer-term single-arm study of 61 patients followed for one to four years confirmed that dextrose prolotherapy provided significant and sustained reduction in pain and constitutional symptoms associated with TMJ hypermobility. Interestingly, imaging showed no change in condyle position or bone shape, suggesting the mechanism involves soft-tissue tightening rather than structural remodeling of the joint itself.14PubMed. Long-term therapeutic effects of dextrose prolotherapy in patients with hypermobility of the temporomandibular joint: a single-arm study with 1-4 years’ follow up Another study found significant reductions in TMJ tenderness and improved clicking and deviation, with no permanent complications.15PubMed Central. Efficacy of Prolotherapy in Temporomandibular Joint Disorders: An Exploratory Study
TMJ prolotherapy is a niche application, and the total number of patients studied remains small. But for people with recurrent jaw dislocation who have exhausted conservative options, the consistency of positive findings and the low complication rate make it worth knowing about.
Sacroiliac and Low Back Pain
The sacroiliac (SI) joint is a common source of low back pain that is notoriously difficult to treat effectively. A study of 103 patients with SI joint instability who had been living with low back pain for a median of two years found that about one in four showed clinically meaningful improvement after prolotherapy, with much of the benefit evident after the first injection.16PubMed. Functional outcome from sacroiliac joint prolotherapy in patients with sacroiliac joint instability A response rate of 23 percent may sound modest, but in a population with chronic, treatment-resistant pain, any therapy that meaningfully helps a quarter of patients is worth considering, especially when the alternative for many is long-term pain medication or fusion surgery.
One of the more striking findings in this area comes from a head-to-head comparison with steroid injections. A randomized controlled trial found that while both prolotherapy and steroid injections provided short-term relief at two weeks, the long-term picture was dramatically different: at 15 months, roughly 59 percent of the prolotherapy group still had at least 50 percent pain relief, compared to only about 10 percent in the steroid group.17PubMed. A randomized controlled trial of intra-articular prolotherapy versus steroid injection for sacroiliac joint pain That finding aligns with a broader narrative in musculoskeletal medicine: corticosteroid injections often provide rapid initial relief but fade, while treatments that stimulate tissue repair may have slower but more durable effects.
How Prolotherapy Stacks Up Against Other Injections
One of the most common questions people ask is whether platelet-rich plasma (PRP) is better than prolotherapy. The answer depends on the condition and the study, but a recurring finding is that the two perform similarly in the medium term. For osteochondral lesions of the talus (cartilage damage in the ankle), a retrospective study found that both PRP and prolotherapy produced comparable improvements in pain and function at one year, with no significant difference between groups, but prolotherapy cost a fraction of PRP per session.18PubMed Central. Comparison of Platelet Rich Plasma and Prolotherapy in the Management of Osteochondral Lesions of the Talus: A Retrospective Cohort Study
For knee osteoarthritis, a study comparing the two found that both significantly improved overall function scores, but PRP was more effective than prolotherapy.19PubMed Central. The effects of injecting intra-articular platelet-rich plasma or prolotherapy on pain score and function in knee osteoarthritis For chronic plantar fasciitis, PRP showed greater initial improvements in disability and function subscales, though both groups improved significantly and the between-group difference did not reach statistical significance.20PubMed. Autologous platelet-rich plasma versus dextrose prolotherapy for the treatment of chronic recalcitrant plantar fasciitis
Compared to corticosteroid injections, a randomized trial for tennis elbow found significant improvements in both prolotherapy and steroid groups at three and six months, with no significant differences between them, though the study was underpowered to detect small differences. About 83 percent of all participants were satisfied with their improvement.21PubMed. Prolotherapy versus corticosteroid injections for the treatment of lateral epicondylosis: a randomized controlled trial A network meta-analysis looking broadly at chronic soft tissue injuries found prolotherapy performed slightly better than corticosteroids and equivalently to blood products at six months, but none of the differences reached statistical significance.22PLoS ONE. Efficacy of prolotherapy in comparison to other therapies for chronic soft tissue injuries: A systematic review and network meta-analysis
The practical takeaway: prolotherapy generally performs in the same ballpark as PRP and somewhat better than steroids in the long run, at a substantially lower cost. PRP may have an edge for certain conditions, but the difference is often not dramatic enough to justify the price gap for many patients.
Neural Prolotherapy Is a Different Animal
While traditional prolotherapy uses concentrated dextrose injected deep into joints or ligament attachments, neural prolotherapy (also called perineural injection therapy) uses very dilute dextrose, typically around 5 percent, injected just under the skin along the path of superficial nerves. The theory is different: rather than triggering an inflammatory cascade, the dilute sugar is thought to directly affect nerve signaling and calm irritated sensory nerves.
A randomized placebo-controlled trial tested ultrasound-guided 5 percent dextrose injections around the perforating cutaneous nerve in patients with chronic tailbone pain. The dextrose group showed significant improvements in pain, pressure-pain threshold, and pain-free sitting time, while the saline control group showed no significant changes. Pain scores dropped from about 82 out of 100 at baseline to about 37 at three months, and pain-free sitting time roughly quadrupled.23PubMed. Ultrasound-guided 5% dextrose neural prolotherapy injection for perforating cutaneous nerve entrapment in chronic coccydynia: a randomized placebo-controlled double-blind trial
A retrospective study of perineural injection therapy for various types of nerve pain found significant pain reductions in most dextrose-treated groups, though patients with complex regional pain syndrome did not respond well.24PubMed Central. The effect of perineural injection therapy on neuropathic pain: a retrospective study A case series of patients with meralgia paresthetica (a compressed nerve causing thigh numbness and burning) found that about two-thirds of treated limbs improved with a single subcutaneous dextrose injection, with all patients experiencing immediate post-injection pain relief.25Egyptian Journal of Neurosurgery. Efficacy of neural prolotherapy in treatment of meralgia paresthetica: a case series
Neural prolotherapy is still in its early research stages, and the evidence base is thin compared to traditional joint prolotherapy. But the low concentration means it stings less, the superficial injection depth means it carries virtually no risk of the serious needle-related complications that can occur with deep injections, and the early controlled data is genuinely promising for specific nerve entrapment conditions.
Safety and What to Expect
Prolotherapy’s safety record is one of its strongest selling points, with an important caveat about where the needle goes. The most common side effects are predictable and temporary: injection-site pain (reported by a majority of patients), stiffness lasting a few days, and occasional bruising.26PubMed. Side effects and adverse events related to intraligamentous injection of sclerosing solutions (prolotherapy) for back and neck pain: A survey of practitioners Higher dextrose concentrations tend to cause more post-injection discomfort and fatigue, while the 5 percent concentration used in neural prolotherapy is described as considerably less painful.27Journal of Anaesthesiology Clinical Pharmacology. Effectiveness and safety of dextrose prolotherapy for chronic spinal pain: A systematic review
Serious complications are rare but not zero. A large practitioner survey cataloguing adverse events from spinal prolotherapy found 472 reported incidents, the vast majority related to needle placement rather than the injected solution. These included spinal headaches, pneumothorax (a punctured lung lining, which is possible when injecting near the upper back and ribs), temporary nerve damage, and in a very small number of cases, permanent nerve injury.26PubMed. Side effects and adverse events related to intraligamentous injection of sclerosing solutions (prolotherapy) for back and neck pain: A survey of practitioners These serious events were overwhelmingly associated with injections in the spine and neck, where the anatomy is unforgiving. For peripheral joints like knees, ankles, and elbows, the safety record across systematic reviews is consistently clean, with multiple reviews reporting zero adverse events across all included studies.
This is an important distinction: prolotherapy into a knee or elbow is a very different risk proposition than prolotherapy along the thoracic spine. If you are considering the treatment, the injection site matters at least as much as the treatment itself when thinking about safety.
Does Ultrasound Guidance Make a Difference
Many prolotherapy injections are performed “blind,” meaning the practitioner uses anatomical landmarks rather than imaging to guide the needle. The question of whether ultrasound guidance improves outcomes has been studied with mixed results. A study of TMJ prolotherapy with 50 percent dextrose found that ultrasound guidance lowered the complication rate compared to blind injection (about 32 versus 52 percent).28PubMed. The Effectiveness of Ultrasound-Guided Temporomandibular Joint Injection in Reduction of Complications Rate Associated With 50% Hypertonic Prolotherapy: Comparative Study However, a separate TMJ study using the same concentration found that both guided and non-guided groups achieved significant pain reduction and improved mouth opening with no meaningful advantage to ultrasound guidance in clinical outcomes.29PubMed. Short Term Clinical Outcomes of Ultrasound-Guided Injection of 50% Hypertonic Prolotherapy in Temporomandibular Joint Internal Derangement: Comparative Study
For knee injections, the picture is cleaner. A study comparing ultrasound-guided and blind intra-articular injections found that for experienced clinicians, accuracy was similar regardless of method. But for less experienced practitioners, ultrasound guidance made a real difference: blind injections by inexperienced clinicians missed the joint space about one in five times, compared to about one in sixteen with ultrasound guidance.30Journal of Anesthesia & Critical Care: Open Access. Accuracy of Ultrasound Guided Versus Blind Knee Intra-articular Injection for Knee Osteoarthritis Prolotherapy If your practitioner is very experienced with prolotherapy, blind injection may be perfectly adequate for accessible joints. If they are newer to the procedure, or the target is in a tricky anatomical location, asking about ultrasound guidance is reasonable.
Why the Research Lags Behind Clinical Practice
Prolotherapy has been used in clinical practice since the mid-20th century, yet the evidence base remains thinner than for many other musculoskeletal treatments. Part of the reason is economic: dextrose is a commodity that cannot be patented, so there is no pharmaceutical company with an incentive to fund large, expensive trials. The research that does exist is largely driven by academic clinicians and small grants, which limits study size and duration.
There are also real methodological challenges. Blinding is difficult because hypertonic dextrose produces a distinctive burning sensation at the injection site that saline does not, so patients in a trial may be able to guess which group they are in. Treatment protocols vary widely between practitioners, with differences in dextrose concentration, injection sites, number of sessions, and whether the injection goes into the joint, around the joint, or both. This heterogeneity makes it hard to pool studies in meta-analyses or to say definitively that “prolotherapy works” as a blanket statement, because the prolotherapy one practitioner delivers may differ substantially from what another practitioner does.
Two early studies of knee osteoarthritis reported improvements in anterior cruciate ligament laxity after prolotherapy, suggesting the treatment may tighten loose ligaments around the joint.31American Journal of Physical Medicine & Rehabilitation. Critical Review of Prolotherapy for Osteoarthritis, Low Back Pain, and other Musculoskeletal Conditions: A Physiatric Perspective But without control groups, those findings cannot be distinguished from natural variation or placebo effects. That kind of gap, where a result is interesting but uncontrolled, characterizes much of the prolotherapy literature. The treatment has moved ahead of the science, which does not mean it does not work, just that proving how well it works has been slow going.
For someone weighing their options, the honest summary is this: prolotherapy is safe for peripheral joints, inexpensive, and supported by encouraging but not bulletproof evidence for knee arthritis, certain tendon problems, TMJ hypermobility, and sacroiliac pain. It is not a miracle cure, and it is not well-suited for every type of musculoskeletal pain. But for the conditions where trials have been done, it consistently outperforms doing nothing and holds its own against treatments that cost considerably more.